VBLT


These 2 Penny Stocks Could Rally Over 100%, Says Oppenheimer

Speaking of economic opportunity, and the general benefits of wide-ranging growth, President John Kennedy once said, “A rising tide lifts all boats.” As …

3 “Strong Buy” Penny Stocks That Offer Massive Potential Gains

The stock market is heating up, and some Wall Street bulls are turning even more positive. Among those adapting an increasingly bullish approach …

This Analyst Presses the ‘Buy’ Button on Vascular Biogenics (VBLT) Stock; Here’s Why

It’s one small step forward for Vascular Biogenics (VBLT), one giant leap for the company’s stock rating. H.

4 Notable Analyst Calls in the Biotech Sector: Loxo Oncology (LOXO), VBL Therapeutics (VBLT), Kalvista Pharmaceuticals (KALV), Aimmune (AIMT)

Investors have been treated like rented mules by the market so far here in October.  More than 75% of the S&P 500 (including …

Vascular Biogenics Ltd/VBL Therapeutics (VBLT) Stock Falls Apart on Underwhelming Clinical Data

Small biotech stocks are often considered “binary” lottery-ticket type events, with either a small chance of big upside, or a much greater probability …

Here’s Why Vascular Biogenics Ltd (VBLT) Stock Is Slumping Today

Shares of Vascular Biogenics Ltd (NASDAQ:VBLT) slumped on Friday, falling 18% as of 10:30 a.m.

Here’s Why Roth Capital Reiterated Buy on Vascular Biogenics (VBLT)

Roth Capital analyst Joseph Pantginis weighed in with a few insights on Vascular Biogenics Ltd (NASDAQ:VBLT), after the Israeli biotech company presented updated data from its Phase …

Oppenheimer Initiates Outperform On Vascular Biogenics, Sets $16 PT

Oppenheimer analyst Yigal Nochomovitz initiated an Outperform rating on Vascular Biogenics (NASDAQ:VBLT) with a $16 price target, which implies an upside of 144% from current levels. Nochomovitz …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts